Dolby Laboratories Lowers FY2026 Adj EPS Guidance from $4.30-$4.45 to $4.25-$4.40 vs $4.30 Est; Narrows FY2026 Sales Guidance from $1.400B-$1.450B to $1.410B-$1.440B vs $1.407B Est

Dolby Laboratories (NYSE:DLB) lowers FY2026 Adj EPS guidance from $4.30-$4.45 to $4.25-$4.40 vs $4.30 analyst estimate. Narrows FY2026 sales outlook from $1.400 billion-$1.450 billion to $1.410 billion-$1.440 billion vs $1.407 billion estimate.